| Document |
Document Title |
|
WO/2023/083102A1 |
The present invention relates to the technical field of medicines, and provides a lipiodol-based active metal microsphere or nano-hydride composite embolic agent, a preparation method therefor and an application thereof. The composite em...
|
|
WO/2023/086562A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor: or a pharmaceutically accept...
|
|
WO/2023/084198A1 |
The present disclosure relates to a method of treating or preventing a disease in an individual, the method comprising reducing pyroptosis by administering to the individual a composition comprising an agent whose administration reduces ...
|
|
WO/2023/082055A1 |
The present invention relates to a pharmaceutical composition containing a β-lactam compound of formula (I), or a stereoisomer, a solvate or a pharmaceutically acceptable salt or ester thereof, and a lactamase inhibitor or efflux pump i...
|
|
WO/2023/086561A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and...
|
|
WO/2023/084531A1 |
The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions compris...
|
|
WO/2023/084459A1 |
This invention relates to methods of treating a method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment a therapeutically effective amount of pexmetinib, or a pharmaceutical...
|
|
WO/2023/085440A1 |
Provided is a therapeutic agent or the like that is for refractory viral infections and that is capable of eliminating or decreasing cccDNA in hepatocytes. This therapeutic agent for refractory viral infections according to the present i...
|
|
WO/2023/061485A9 |
Provided are a rejuvenated skeletal muscle cell, a method for producing the rejuvenated skeletal muscle cell, and the use thereof.
|
|
WO/2023/083296A1 |
The present application provides the use of a PDE4 inhibitor (e.g., a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof) in the preparation of a drug for reducing uric acid levels and preventing uric acid lev...
|
|
WO/2023/084515A1 |
The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical...
|
|
WO/2023/086433A1 |
Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI) and methods of treating conditions associated with central hypoventilation are described herein.
|
|
WO/2023/079428A1 |
The present disclosure relates to combination therapies useful for the treatment of cancers. The combination therapy comprises a PD-1 axis binding antagonist, in combination with a Toll-like receptor 7/8 (TLR7/8) agonist or a pharmaceuti...
|
|
WO/2023/080895A1 |
Provided herein are pharmaceutical compositions comprising: (a)a natural killer cell (NK cell) comprising a KIR-B haplotype and expression of a CD16 molecule; and (b)a bispecific antibody or antigen binding fragment thereof comprising a ...
|
|
WO/2023/081486A1 |
The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds. Also provided are methods of using the combinations with Cbl-b compounds ...
|
|
WO/2023/081757A1 |
The present disclosure relates to PI3Ka inhibitors, the crystalline forms, salts, and cocrystals thereof, and the compositions and methods of making and use thereof.
|
|
WO/2023/078881A1 |
The present invention is directed to (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)o
xy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, wherein th...
|
|
WO/2023/080263A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cataract, the composition comprising a substance for increasing expression of NFAT5 mRNA or protein, thereby inhibiting necrosis of crystalline lens...
|
|
WO/2023/078464A1 |
Disclosed are an epsilon-poly-L-lysine-based drug conjugate, an intermediate thereof, and an application thereof. The present invention provides an epsilon-poly-L-lysine derivative-drug conjugate that has a controllable group coupling nu...
|
|
WO/2023/081117A1 |
Provided herein are methods of improving sensitivity to immune checkpoint blockade (ICB) in a subject with a solid tumor cancer, the method comprising: administering to the subject with a solid tumor cancer an inhibitor of a tumor immune...
|
|
WO/2023/078557A1 |
The present invention provides methods and systems for the treatment of patients suffering from a condition characterized by the presence of vitreous floaters in the patients' eye and includes a ready-to-use topical ophthalmic formulatio...
|
|
WO/2023/081901A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2023/080765A1 |
The present invention pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used to treat NADPH oxidase (NOX)-related diseases...
|
|
WO/2023/003815A9 |
In some aspects, the disclosure relates to compositions and methods for decreasing a risk of telangiectasia in a patient receiving a therapeutically effective amount of an ActRII polypeptide, particularly a dosing regimen that decreases ...
|
|
WO/2023/077413A1 |
Provided are a protein containing an amino acid sequence capable of binding to a peptide fragment of a substrate GPRP, a fibrinogen-like protein 1 (FGL1) containing the amino acid sequence, and a fibrinogen domain (FD) of the FGL1, where...
|
|
WO/2023/078821A1 |
In the management of patients with inflammatory bowel diseases (IBD), there is a need to identify druggable biological pathways to improve mucosal repair and efficacy of TNF alpha biologics. Based on the VIVA transgenic model of Vnn1 ove...
|
|
WO/2023/079187A1 |
The invention relates to a composition comprising a synergistic combination of fluoroethylnormemantine (FENM) and of at least one acetylcholinesterase inhibitor. More particularly, the invention relates to said composition for use thereo...
|
|
WO/2023/078180A1 |
The present invention belongs to the technical field of drugs, and specifically relates to a mini-tablet, and a preparation method therefor and a formulation thereof. The components of the mini-tablet comprises an active ingredient, a fi...
|
|
WO/2023/080703A1 |
The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously use...
|
|
WO/2023/078426A1 |
Provided in the present invention are a compound, a pharmaceutical composition containing same, and the use thereof. The compound interferes with the interaction between the menin protein and MLL1 or MLL2 or a MLL fusion oncoprotein, and...
|
|
WO/2023/081801A2 |
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients, wherein the patient is about 4 years old to less than about 12 years old. Provided herein are methods of using voxelotor for the treatme...
|
|
WO/2023/078941A1 |
The present invention relates to a new compound for the inhibition of the transmission of malaria in humans, a pharmaceutical composition comprising said compound, and a method for the inhibition of the transmission of malaria in humans ...
|
|
WO/2023/078807A1 |
The present invention relates to a pharmaceutical composition comprising a class Ila HDAC inhibitor characterised by a trifluoromethyloxadiazole group and/or 5-Aza-2-deoxycytidine for use in treating myopathy.
|
|
WO/2023/080157A1 |
The present invention pertains to a therapeutic or prophylactic for HTLV-1-associated myelopathy (HAM), said therapeutic or prophylactic including a substance that inhibit the activity of the MAPK signaling pathway in which mitogen-activ...
|
|
WO/2023/081676A1 |
The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an ...
|
|
WO/2023/080753A1 |
The present invention relates to a pharmaceutical kit for parenteral co-administration, comprising a first formulation comprising a first drug, and a second formulation comprising a second drug and a parenteral drug delivery system. Due ...
|
|
WO/2023/075122A1 |
The present invention relates to a novel use of AFAP1 antisense RNA1 (AFAP1-AS1) and MLK7 antisense RNA1 (MLK7-AS1) as targets for treatment and metastasis inhibition of colorectal cancer, and, more particularly, to a kit for diagnosing ...
|
|
WO/2023/072240A1 |
Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.
|
|
WO/2023/072872A1 |
The present invention relates to a tadalafil oral suspension comprising 0.01-5 % w/v of tadalafil, a cyclodextrin, coprocessed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as vehicle. The suspensio...
|
|
WO/2023/077172A2 |
|
|
WO/2023/073526A1 |
Provided herein are methods for improving delivery of a pharmaceutical composition to the central nervous system of a subject in need thereof, the method comprising administering to the subject an agent that enhances glymphatic influx in...
|
|
WO/2023/076243A1 |
The present invention relates generally to methods for reducing, minimizing, preventing, ameliorating, or eliminating one or more side effects associated with administration of an apical sodium-dependent bile acid transporter inhibitor (...
|
|
WO/2023/076329A1 |
The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.
|
|
WO/2023/074794A1 |
The present disclosure provides a novel treatment for diabetes. The present disclosure provides a treatment for diabetes, in which blood sugar control and HDAC adjustment are combined. According to one embodiment, the present disclosure ...
|
|
WO/2023/076765A1 |
This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer thera...
|
|
WO/2023/076404A1 |
Provided is a method for treating systemic lupus erythematosus (SLE) in a patient in need thereof comprising administering a therapeutically effective amount of a leucine-rich repeat kinase 2 (LRRK2) inhibitor.
|
|
WO/2023/076620A1 |
Described herein are hydrogel capsule compositions which comprise a population of hydrogel capsules and a pharmaceutically acceptable solution. The hydrogel capsules in the population comprise a hydrogel-forming polymer and encapsulate a...
|
|
WO/2023/073134A2 |
The present invention concern endothelin receptor antagonists for use in the treatment or the prevention of muscle fibrosis.
|
|
WO/2023/076556A1 |
The present invention provides compounds, compositions thereof, and processes for preparing same.
|
|
WO/2023/072010A1 |
The use of a PPAR agonist in the preparation of a drug for treating acute myeloid leukemia.
|
